Pharmacokinetics of N4-octadecyl-1-β-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice

Journal of Pharmacy and Pharmacology

Volumn 49, Issue 11, 1997, Pages 1076-1081

  Rentsch, Katharina M ^a   Schwendener, Reto A ^b   Schott, Herbert ^c   Hänseler, Edgar ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE DERIVATIVE; LIPOSOME; ANTINEOPLASTIC AGENT; CYTARABINE; DRUG DERIVATIVE; N(4) OLEYLCYTOSINE ARABINOSIDE; N(4)-OLEYLCYTOSINE ARABINOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ERYTHROCYTE LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; TUMOR XENOGRAFT; ANIMAL; BIOAVAILABILITY; BLOOD; COMPARATIVE STUDY; INSTITUTE FOR CANCER RESEARCH MOUSE; INTESTINE ABSORPTION; METABOLIC CLEARANCE RATE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTARABINE; FEMALE; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED ICR;

EID: 0030608798     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1997.tb06045.x     Document Type: Article

References (33)

1. 4-acyl-1-β-D-arabinofuranosylcytosine. Cancer Res. 36: 2726-2732
2. Bolwell, B. J., Cassileth, P. A., Gale, R. P. (1988) High-dose cytarabine: a review. Leukemia 2: 253-260
3. DeAngelis, L. M., Kreis, W., Chan, K., Dantis, E., Akerman, S. (1992) Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother. Pharmacol. 29: 173-177
4. Dedrick, R. L., Bischoff, K. B., Zaharko, D. S. (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother. Rep. 54: 95-101
5. Gish, D. T., Kelly, R. C., Camiener, G. W., Wechter, W. J. (1971) Nucleic acids. 11. Synthesis of 5′-esters of 1-beta-D-arabinofuranosylcytosine possessing antileukemic and immunosuppressive activity. J. Med. Chem. 14: 1159-1162
6. Ho, D. H., Frei, E. (1971) Clinical pharmacology of 1-β-D-arabinofuranosyl cytosine. Clin. Pharmacol. Ther. 12: 944-954
7. Hong, C. I., Nechaev, A., West, C. R. (1979) Nucleoside conjugates as potential antitumor agents. 2. Synthesis and biological activity of 1-(β-D-arabinofuranosyl)cytosine conjugates of prednisolone and prednisone. J. Med. Chem. 22: 1428-1432
8. 4-hexadecyl-1-β-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes. J. Pharm. Pharmacol. 47: 282-288
9. 4-hexadecyl-1-β-D-arabinofuranosylcytosine, a lipophilic derivative of 1-β-D-arabinofuranosylcytosine. Br. J. Cancer 71: 957-962
10. 4-hexadecyl-1-β-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937. Cancer Chemother. Pharmacol. 36: 483-492
11. 4-substituted 2,2′-anhydronucleosides. J. Med. Chem. 17: 1076-1078
12. 4-behenoyl-1-β-D-arabinofuranosylcytosine. Recent Results Cancer Res. 70: 147-51
13. Kaufmann-Kolle, P., Drevs, J., Berger, M. R., Kötting, J., Marschner, N., Unger, C., Eibl, H. (1994) Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol. 34: 393-398
14. Keating, M. J., McCredie, K. B., Bodey, G. P., Smith, T. L., Gehan, E., Freireich, E. J. (1982) Improved prospects for long-term survival in adults with acute myelogenous leukemia. J. Am. Med. Assoc. 248: 2481-2486
15. 4-octadecyl-1-β-D-arabinofuranosylcytosine (NOAC), a new anticancer drug. J. Pharmacol. Exp. Ther. In press
16. Kreis, W., Chan, K., Budman, D. R., Schulman, P., Allen, S. L., Weiselberg, L., Lichtman, S., Henderson, V., Freeman, J., Deere, M., Andreeff, M., Vinciguerra, V. (1988) Effect of tetrahydrouridine on the clinical pharmacology of 1-β-D-arabinofuranosylcytosine when both drugs are co-infused over three hours. Cancer Res. 48: 1337-1342
17. Marsh, J. H., Kreis, W., Barile, B., Akerman, S., Schulman, P., Allen, S. L., DeMarco, L. C., Schuster, M. W., Budman, D. R. (1993) Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother. Pharmacol. 31: 481-484
18. Matsushita, T., Ryu, E. K., Hong, C. F., MacCoss, M. (1981) Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Cancer Res. 41: 2707-2713
19. Momparler, R. L. (1974) A model for the chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Res. 34: 1775-1787
20. Plunkett, W., Gandhi, V. (1993) Cellular pharmacodynamics of anticancer drugs. Semin. Oncol. 20: 50-63
21. 4-octadecyl-1-β-D-arabinofuranosylcytosine in plasma and erythrocytes. J. Chromatogr. B 673: 259-266
22. Roos, A., Hinderling, P. H. (1981) Protein binding and erythrocyte partitioning of the antirheumatic proquazone. J. Pharm. Sci. 70: 252-257
23. 4-acyl and 2,2′-anhydro-3′-O-acyl derivatives as potential prodrugs. J. Med. Chem. 25: 171-178
24. Rubas, W., Supersaxo, A., Weder, H. G., Hartmann, H. R., Hengartner, H., Schott, H., Schwendener, R. (1986) Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes. Int. J. Cancer 37: 149-154
25. Schott, H., Häussler, M. P., Schwendener, R. A. (1994) Synthese von 4-Alkylcytosinnucleosiden und deren cytostatische Wirkung im L1210 Leukämiemodell der Maus. Liebigs Ann. Chem. 465-470
26. 4-hexadecyl-1-β-D-arabinofuranosylcytosine. Int. J. Cancer 51: 466-469
27. 4-oleyl-cytosine arabinoside. In: Lopez-Berenstein, G., Fidler, I. J. (eds) Liposomes in the Therapy of Infectious Diseases and Cancer, Alan R. Liss Inc., New York, pp 95-105
28. 4-alkyl derivatives of 1-β-D-arabinofuranosylcytosine. J. Cancer Res. Clin. Oncol. 122: 102-108
29. Thomson, A. B. R., Schoeller, C., Keelan, M., Smioth, L., Clandinin, M. T. (1993) Lipid absorption: passing through the unstirred layers, brush border membrane, and beyond. Can. J. Physiol. Pharmacol. 71: 531-555
30. 4-stearoyl-1-β-D-arabinofuranosylcytosine as new antitumor agents. In: Grassi, J. D. (ed.) Current Chemotherapy and Infectious Diseases. The American Society of Microbiology, Washington DC, pp 1591-1593
31. Wagner, J. G., Nelson, E. (1963) Per cent absorbed time plots derived from blood level and/or urinary excretion data. J. Pharm. Sci. 52: 610-611
32. 4-substituted derivatives of 1-β-D-arabinofuranosyl cytosine and -5-fluorocytosine. J. Med. Chem. 11: 144-148
33. 4-behenoyl-1-beta-D-arabinofuranosylcytosine. Recent Results Cancer Res. 70: 219-229